Bolt Biotherapeutics CMO, Dr. Edith Perez, and VP of CMC & Quality, Dr. Nathan Ihle, bring a unique combination of patient and production process expertise to the table for an enlightening conversation on preparing chemistry, manufacturing, and controls for an IND and ensuing first-in-human studies.
|